Literature DB >> 12207114

Intrathecal bradykinin administration: opposite effects on nociceptive transmission.

Urszula Sot1, Krystyna Misterek, Stanislow Witold Gumułka, Anna Dorociak.   

Abstract

Injected intrathecally, bradykinin (BK) produced either hyperalgesia (0.15 microg) or antinociception (6.0 microg) in rats when thermal noxious stimuli were used. Similarly, des-Arg(9)-BK at the lower dose (0.15 microg) decreased, whereas at the higher dose (6.0 microg) it increased the threshold to thermal noxious stimuli; however, these effects were less pronounced than those of BK. The antinociception induced by BK was abolished by HOE 140, a B(2) receptor antagonist, injected intrathecally at a dose of 1.3 ng and was markedly attenuated by des-Arg(10)-HOE 140, a B(1) receptor antagonist (1.15 ng i.t.). The results obtained in this study showed that--depending on the dose used--BK and des-Arg(9)-BK could produce pro- as well as antinociceptive actions. Both B(2) and B(1) receptors are involved in the action of intrathecally applied BK. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12207114     DOI: 10.1159/000065629

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  3 in total

Review 1.  Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes.

Authors:  João B Calixto; Rodrigo Medeiros; Elizabeth S Fernandes; Juliano Ferreira; Daniela A Cabrini; Maria M Campos
Journal:  Br J Pharmacol       Date:  2004-11-01       Impact factor: 8.739

Review 2.  Pronociceptive actions of dynorphin via bradykinin receptors.

Authors:  Josephine Lai; Miaw-chyi Luo; Qingmin Chen; Frank Porreca
Journal:  Neurosci Lett       Date:  2008-04-08       Impact factor: 3.046

3.  Spinal dynorphin and bradykinin receptors maintain inflammatory hyperalgesia.

Authors:  Miaw-Chyi Luo; Qingmin Chen; Michael H Ossipov; David R Rankin; Frank Porreca; Josephine Lai
Journal:  J Pain       Date:  2008-10-31       Impact factor: 5.820

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.